The branded version of the product had $50 million sales over the past twelve months.
Other-the-counter pharmaceuticals company Perrigo Co. (Agis Industries) (Nasdaq:PRGO; TASE:PRGO) has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic version of vaginal yeast infection treatment Monistat 1. Perrigo's application was filed for a generic version of the Monistat 1 combination pack - an antifungal cream and suppository. Perrigo is apparently the first company to challenge the patent held by McNeil PPC Inc.
Perrigo said the cream had sales of approximately $50 million for the 12 months ended March 2008. The company added that McNeill filed suit alleging patent infringement in the United States District Court for the District of New Jersey last Friday to prevent it from proceeding with the commercialization of its product.
Perrigo's share closed down 0.04% on Nasdaq yesterday, giving the company a market cap of $3.73 billion. The company's share was down 1.6% in morning trading on the Tel Aviv Stock Exchange (TASE).
Published by Globes [online], Israel business news - www.globes-online.com - on April 22, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008